Sex: M
Vaccine: COVID19, FLU3, FLUX, PPV, VARZOS, COVID19, FLU3, FLUX, PPV, VARZOS
Symptoms: Gait disturbance, Guillain-Barre syndrome, Nausea, Pain in extremity, Pyrexia
Clinical narrative: the patient need about 3 people to help him walk; sore arm; feeling abnormal; chills; nausea; fever (101.7 F); energy and streng have not been fully regained; symptoms were like Guillain-Barre syndrome; This spontaneous report was received from a consumer via manufacturer and refers to an adult male patient of unknown age.  The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On an unknown date in 2021, the patient was vaccinated with a dose of influenza vaccine (FLUZONE) administered intramuscularly on the left deltoid (strength, dosage regimen, formulation, lot #, and expiry date were not provided); influenza vaccine (strength, dosage regimen, anatomical location, formulation, lot #, expiry date, and route of administration were not provided); and  covid-19 vaccine, administered (strength, formulation, lot #, expiry date, anatomical location, and route of administration were not provided). On an unknown date in July 2021 (also reported as "about a year ago"), the patient was vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) (strength, dosage regimen, lot #, expiry date, anatomical location, and route of administration were not provided). On 28-OCT-2021, the patient was vaccinated with a dose of varicella zoster vaccine (SHINGRIX) intramuscularly (strength, formulation, dosage regimen, lot #, anatomical location, and expiry date were not provided) all vaccines were administered as prophylaxis.  On 29-OCT-2021 (also reported as "following the administration of influenza vaccine [FLUZONE], pneumococcal vaccine, polyvalent [23-valent] [PNEUMOVAX23], varicella zoster vaccine [SHINGRIX], COVID-19 vaccine, and influenza vaccine"), the patient experienced chills, fever of 101.7 farenheit degree, nausea, a sore arm, and his energy and strengh had not been fully regained (asthenia), he was feeling abnormal, and needed about 3 people to help him walk (difficulty in walking). On the same date, the patient was hospitalized (conflicting information, also reported as "emergency room") at around 4:00 pm for all the events. On 29-OCT-2021, the patient was discharged from the hospital, at 9:30 pm. The reporter stated that Guillan-Barre syndrome had not been diagnosed, but he thinks that symptoms were like Guillain-Barre syndrome. The reported stated that the patient received the 1st and 2nd dose of COVID-19 vaccine but did not had any major reaction other than a sore arm. On an unspecified date, the patient underwent a scan that showed there were no sings of stroke. On an unknown date, a blood test was normal.  The outcome of the events chills, fever, nausea, feeling abnormal, and difficulty in walking was reported as resolved. At the time of the report, the outcome of the event asthenia was not resolved, and the outcome of the event pain in extremity was unknown.  The causal relationship between the events and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was unknown.  The reported considered that the event of difficulty in walking was disabling.  Upon internal review, the event of Guillain-Barre syndrome was considered to be medically significant.